BioVie Fully Enrolls Parkinson’s Trial, Targets First New Therapy in 50 Years | Top-Line Data Soon

For biotech investors and healthcare innovators, this New to The Street interview features BioVie Pharma leadership discussing a major milestone: full enrollment of a Parkinson’s disease clinical trial evaluating its drug candidate as a first-line therapy. The company shares promising results from earlier studies showing improved muscle control and morning mobility, outlines an innovative in-home clinical trial model designed to speed enrollment and improve data quality, and explains why upcoming top-line data could represent a breakthrough for Parkinson’s patients after decades without a new therapeutic option.

#NewToTheStreet
#BioVie
#ParkinsonsDisease
#Biotech
#ClinicalTrials
#NeurodegenerativeDisease
#DrugDevelopment
#HealthcareInnovation
#MedicalResearch
#PharmaNews
#BiotechStocks
#ParkinsonsResearch
#ClinicalMilestone
#InvestorInsights